JP2022502498A5 - - Google Patents

Info

Publication number
JP2022502498A5
JP2022502498A5 JP2021540394A JP2021540394A JP2022502498A5 JP 2022502498 A5 JP2022502498 A5 JP 2022502498A5 JP 2021540394 A JP2021540394 A JP 2021540394A JP 2021540394 A JP2021540394 A JP 2021540394A JP 2022502498 A5 JP2022502498 A5 JP 2022502498A5
Authority
JP
Japan
Prior art keywords
composition according
less
days
treatment cycle
cytarabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021540394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502498A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/052952 external-priority patent/WO2020068979A1/en
Publication of JP2022502498A publication Critical patent/JP2022502498A/ja
Publication of JP2022502498A5 publication Critical patent/JP2022502498A5/ja
Pending legal-status Critical Current

Links

JP2021540394A 2018-09-25 2019-09-25 血液疾患の低強度治療 Pending JP2022502498A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862736393P 2018-09-25 2018-09-25
US62/736,393 2018-09-25
US201862772372P 2018-11-28 2018-11-28
US62/772,372 2018-11-28
PCT/US2019/052952 WO2020068979A1 (en) 2018-09-25 2019-09-25 Low-intensity treatment of hematological disorders

Publications (2)

Publication Number Publication Date
JP2022502498A JP2022502498A (ja) 2022-01-11
JP2022502498A5 true JP2022502498A5 (https=) 2022-09-30

Family

ID=69950910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540394A Pending JP2022502498A (ja) 2018-09-25 2019-09-25 血液疾患の低強度治療

Country Status (11)

Country Link
US (3) US20240252522A1 (https=)
EP (1) EP3856198A4 (https=)
JP (1) JP2022502498A (https=)
KR (1) KR20210065962A (https=)
CN (1) CN113164502A (https=)
AU (1) AU2019350759A1 (https=)
BR (1) BR112021005539A2 (https=)
CA (1) CA3114002A1 (https=)
IL (1) IL281729A (https=)
MX (1) MX2021003527A (https=)
WO (1) WO2020068979A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10927418B2 (en) * 2015-11-11 2021-02-23 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
CN113164502A (zh) * 2018-09-25 2021-07-23 塞拉特药物股份有限公司 血液病的低强度治疗
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
CA3216716A1 (en) 2021-05-03 2022-11-10 Tim BERGBREDE Composition comprising an inhibitor of mitochondrial transcription

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2002331481B2 (en) 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
ES2387886T3 (es) 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
EP2407169A1 (en) 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
PL3300601T3 (pl) * 2007-02-16 2022-05-02 Rotalec Ip Holdings Llc Ustalone stosunki leków do leczenia nowotworów hematopoetycznych i zaburzeń proliferacyjnych
SI2768484T1 (sl) 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Liofilizirani liposomi
US10927418B2 (en) * 2015-11-11 2021-02-23 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
AU2017302668B9 (en) * 2016-07-28 2023-06-22 Novartis Ag Combination therapies of chimeric antigen receptors and PD-1 inhibitors
JP6411702B1 (ja) 2016-12-01 2018-10-24 Jxtgエネルギー株式会社 全芳香族液晶ポリエステル樹脂
CN113164502A (zh) * 2018-09-25 2021-07-23 塞拉特药物股份有限公司 血液病的低强度治疗
US11980636B2 (en) * 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Similar Documents

Publication Publication Date Title
JP2022502498A5 (https=)
JP2023041862A5 (https=)
JP2021066744A5 (ja) ブプロピオンおよびデキストロメトルファンを含む組成物
JP2023541430A5 (https=)
KR20090057349A (ko) 레보도파/칼비도파의 24시간의 장기간 장내투여
BR0207024A (pt) Medicamento com ação inicial rápida para o tratamento de disfunção sexual
JP2021512149A5 (https=)
RU2010147287A (ru) Комбинированная композиция
JP2005506367A5 (https=)
JP2015513309A5 (https=)
JP3465824B2 (ja) 腫瘍治療用医薬組成物
Oguchi et al. Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis
JP2023552700A5 (https=)
JP2019515909A5 (https=)
WO2011159100A2 (ko) 항암 활성을 나타내는 약제학적 조성물
Murty Antiepileptic overdose
JP2018138596A5 (https=)
JP2016505050A5 (https=)
JPWO2021045159A5 (https=)
CN107137417B (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2011500589A5 (https=)
JP2014534229A5 (https=)
JP2008517991A5 (https=)
JP2023505301A5 (https=)
RU2181588C2 (ru) Способ профилактики отсроченной рвоты